SCHEMBL27189554

SCHEMBL27189554

CN(C)CCc1c[nH]c2c(CCF)ccc(OCc3ccccc3)c12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.64
HTR1D P28221 3/20 0.48
TRPM8 Q7Z2W7 2/20 0.48
LTA4H P09960 1/20 0.44
PLA2G2A P14555 1/20 0.44
HTR1A P08908 4/20 0.42
SLC6A4 P31645 1/20 0.42
HTR6 P50406 3/20 0.41
HTR2C P28335 3/20 0.40
HTR2B P41595 3/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
BLM P54132 1/20 0.38
DRD1 P21728 1/20 0.38
HTR1B P28222 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27189585 0.89 HTR2A (0.66) HTR2AHTR1DTRPM8LTA4HPLA2G2A
SCHEMBL1163398 0.86 HTR2A (0.66) HTR2AHTR1DTRPM8LTA4HPLA2G2A
SCHEMBL27189752 0.85 HTR2A (0.59) HTR2AHTR1DTRPM8LTA4HPLA2G2A
SCHEMBL27189518 0.85 HTR2A (0.67) HTR2AHTR1DTRPM8LTA4HPLA2G2A
SCHEMBL27189566 0.85 HTR2A (0.61) HTR2AHTR1DTRPM8LTA4HPLA2G2A
SCHEMBL27189559 0.84 HTR2A (0.66) HTR2AHTR1DTRPM8LTA4HPLA2G2A
SCHEMBL27189549 0.81 HTR2A (0.62) HTR2AHTR1DTRPM8LTA4HPLA2G2A
SCHEMBL27189536 0.80 HTR2A (0.60) HTR2AHTR1DTRPM8LTA4HPLA2G2A
SCHEMBL27189543 0.78 HTR2A (0.41) HTR2ATRPM8LTA4HPLA2G2ACYP2C9
SCHEMBL12558834 0.78 HTR2A (1.00) HTR2AHTR1DTRPM8HTR1ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059217-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF BRIGHT MINDS BIOSCIENCES INC. (CA) 2025-02-20 US disclosed
CN-117897376-A Heterocyclic compounds and process for preparing same 光明智慧生物科学公司 2024-04-16 CN disclosed
EP-4347561-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF Bright Minds Biosciences Inc. (CA) 2024-04-10 EP disclosed
WO-2022246554-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF BRIGHT MINDS BIOSCIENCES INC. (CA) 2022-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059217-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF OPRL1, OPRK1, CNR2 HTR2A 413/4885HTR1D 409/4885TRPM8 2582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.